Program
enlicitide
Also written as “Enlicitide”.
Its studies are mostly in Renal Insufficiency · Hyperlipidemias · Hepatic Insufficiency · Hypercholesterolemia, led by Merck.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Merck | 143 open or running | phase 3since Jun 4, 2024 | Jun 4, 2024 | Dec 14, 2026phase 1 · NCT07776665 |
Also a collaborator on its studies: celerion.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jun 4, 2024First study: phase 3 study in HypercholesterolemiaFirst studyNCT06450366 · 301 enrolled · United States, Argentina, Canada and more
- Aug 26, 2024Phase 1 study in Hepatic InsufficiencyNCT06575959 · 20 enrolled · United States
- Sep 12, 20242 phase 1 studies in HealthyNCT06597760, NCT06609512
- Oct 14, 2024Phase 1 study in Renal InsufficiencyNCT06643377 · 27 enrolled · United States
- Dec 2, 2024Phase 1 study in HealthyNCT06719544 · 16 enrolled · United States
- Mar 12, 2025Phase 1 study in HealthyNCT06880874 · 40 enrolled · United States
- Jun 26, 2025Phase 1 study in HealthyNCT07044479 · 60 enrolled · United States
- Oct 10, 2025Phase 3 study in HyperlipidemiasNCT07216482 · 996 enrolled · United States, Argentina, Australia and more
- Dec 10, 2025Phase 1 study in HealthyNCT07300280 · 60 enrolled · United States
- Mar 16, 2026Phase 1 study in HealthyNCT07481708 · 30 enrolled · United States
- May 22, 2026Phase 2 study in Lipoprotein(a)NCT07614984 · 750 planned · United States, Canada, Colombia and more
- May 27, 2026Phase 1 study in HealthyNCT07619443 · 30 enrolled · United States
- Aug 17, 2026Phase 1 study in HealthyNCT07776665 · 30 enrolled · United States
Ahead
- Dec 14, 2026Primary completion: phase 1 study in HealthyNCT07776665
- Oct 12, 2027Primary completion: phase 2 study in Lipoprotein(a)NCT07614984
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 14 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07776665Healthy · United States | 1 | Active, not recruiting | Dec 14, 2026 | 30 |
| NCT07619443Healthy · United States | 1 | Completed | Sep 5, 2026 | 30 |
| NCT07614984Lipoprotein(a) · United States, Canada, Colombia and more | 2 | Recruiting | Oct 12, 2027 | 750 |
| NCT07481708Healthy · United States | 1 | Completed | May 18, 2026 | 30 |
| NCT07300280Healthy · United States | 1 | Completed | Oct 14, 2026 | 60 |
| NCT07216482Hyperlipidemias · United States, Argentina, Australia and more | 3 | Active, not recruiting | Aug 3, 2026 | 996 |
| NCT07044479Healthy · United States | 1 | Completed | Aug 13, 2025 | 60 |
| NCT06880874Healthy · United States | 1 | Completed | May 16, 2025 | 40 |
| NCT06719544Healthy · United States | 1 | Completed | Jan 27, 2025 | 16 |
| NCT06643377Renal Insufficiency · United States | 1 | Completed | Jun 25, 2025 | 27 |
| NCT06609512Healthy · United States | 1 | Completed | Jan 13, 2025 | 20 |
| NCT06597760Healthy · United States | 1 | Completed | Nov 1, 2024 | 24 |
| NCT06575959Hepatic Insufficiency · United States | 1 | Completed | May 1, 2025 | 20 |
| NCT06450366Hypercholesterolemia · United States, Argentina, Canada and more | 3 | Completed | Feb 14, 2025 | 301 |
How it is read
Names in the registry
- “Enlicitide”, 13 entries
- “enlicitide”, 1 entry
Conditions, from the studies’ own filings
- Renal Insufficiency, 1 study
- Hyperlipidemias, 1 study
- Hepatic Insufficiency, 1 study
- Hypercholesterolemia, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.